Global Leukapheresis

Leukapheresis Comprehensive Study by Type (Leukapheresis Disposables, Leukapheresis Devices (Apheresis Devices, Leukapheresis Columns & Cell Separators and Other)), Application (Research Institute, Therapeutic Applications), End User (Academic and Research Institutes, Blood Component Providers and Blood Centers, Pharmaceutical and Biotechnology Companies, Hospitals and Transfusion Centers) Players and Region - Global Market Outlook to 2030

Leukapheresis Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 7.1%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Leukapheresis
Leukapheresis, a procedure which is used to separate and collect white blood cells. It is highly used in the treatment of CAR (chimeric antigen receptor) T-cell therapy. Increasing demand for leukopaks in the development of cell-based therapies is the major driving factor in the growth of the leukapheresis market. Moreover, surging incidences of leukemia cancer has risen significantly in the past recent years which might provide lucrative opportunity to drive the very market worldwide.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
CAGR7.1%


The global behavioral rehabilitation market is highly fragmented. There exists a large number of players in the market. However, recent times have witnessed a considerable number of mergers and acquisitions. Analyst at AMA Research estimates that Global Players will contribute the maximum growth to Global Leukapheresis market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Asahi Kasei Medical (Japan), Fresenius (Germany), Haemonetics (United States), Terumo BCT (United States), STEMCELL Technologies (Canada), Macopharma (France), HemaCare (United States), AllCells (United States), StemExpress (United States) and PPA Research Group (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Key Biologics (United States), Caltag Medsystem (United Kingdom), ZenBio (United States), Precision for Medicine (United States) and BioIVT (United States).

Segmentation Overview
AMA Research has segmented the market of Global Leukapheresis market by Type (Leukapheresis Disposables and Leukapheresis Devices (Apheresis Devices, Leukapheresis Columns & Cell Separators and Other)), Application (Research Institute and Therapeutic Applications) and Region.



On the basis of geography, the market of Leukapheresis has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by End User, the sub-segment i.e. Academic and Research Institutes will boost the Leukapheresis market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
The Growth in Demand for Leukopaks in Clinical Research

Market Growth Drivers:
Surging Incidence and Prevalence of Leukemia and The Growth in Number of Blood Donations Worldwide

Challenges:
Dearth of Qualified Doctors in Emerging and Underdeveloped Economies, High Cost of Cellular Immunotherapies and Blood Transfusion Safety in Developing Countries

Restraints:
High Cost of Therapeutic Leukapheresis and Leukopaks and Stringent Recruitment Criteria for Donor Act

Opportunities:
Increasing Use of Leukapheresis in Pediatric Patients in both Developed and Developing Nations and Growing Policies on Reimbursements and Increasing Number of Complex Surgeries

Market Leaders and their expansionary development strategies
In January 2023, Sanguine Biosciences ("Sanguine"), a leader in connecting patients with biopharmaceutical companies to accelerate precision medicine R&D and Cell & Gene Therapy, announced today a new investment from BroadOak Capital Partners, LLC ("BroadOak"), a leading direct investment and advisory firm focused on life science research tools, pharmaceutical services and diagnostics. The partnership with BroadOak enables Sanguine to expand its laboratory operations, leukapheresis offerings, and patient donor network.
In May 2023, Akadeum Life Sciences, a global leader in buoyancy-based cell separation and activation technology, is announcing the launch of a new series of products for cell therapy research and development—enabling direct leukopak human immune cell isolation and T-cell activation/expansion kits at the American Society of Gene + Cell Therapy’s


Key Target Audience
Apheresis Device Manufacturers and Distributors, Leukapheresis Product Manufacturers and Distributors, Cancer Treatment Centers, Blood Component Providers & Blood Centers, Academic And Research Institutes, Government Associations, Pharmaceutical and Biotechnological Companies and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Leukapheresis Disposables
  • Leukapheresis Devices (Apheresis Devices, Leukapheresis Columns & Cell Separators and Other)
By Application
  • Research Institute
  • Therapeutic Applications
By End User
  • Academic and Research Institutes
  • Blood Component Providers and Blood Centers
  • Pharmaceutical and Biotechnology Companies
  • Hospitals and Transfusion Centers

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Surging Incidence and Prevalence of Leukemia
      • 3.2.2. The Growth in Number of Blood Donations Worldwide
    • 3.3. Market Challenges
      • 3.3.1. Dearth of Qualified Doctors in Emerging and Underdeveloped Economies
      • 3.3.2. High Cost of Cellular Immunotherapies
      • 3.3.3. Blood Transfusion Safety in Developing Countries
    • 3.4. Market Trends
      • 3.4.1. The Growth in Demand for Leukopaks in Clinical Research
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Leukapheresis, by Type, Application, End User and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Leukapheresis (Value)
      • 5.2.1. Global Leukapheresis by: Type (Value)
        • 5.2.1.1. Leukapheresis Disposables
        • 5.2.1.2. Leukapheresis Devices (Apheresis Devices, Leukapheresis Columns & Cell Separators and Other)
      • 5.2.2. Global Leukapheresis by: Application (Value)
        • 5.2.2.1. Research Institute
        • 5.2.2.2. Therapeutic Applications
      • 5.2.3. Global Leukapheresis by: End User (Value)
        • 5.2.3.1. Academic and Research Institutes
        • 5.2.3.2. Blood Component Providers and Blood Centers
        • 5.2.3.3. Pharmaceutical and Biotechnology Companies
        • 5.2.3.4. Hospitals and Transfusion Centers
      • 5.2.4. Global Leukapheresis Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Leukapheresis: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Asahi Kasei Medical (Japan)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Fresenius (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Haemonetics (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Terumo BCT (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. STEMCELL Technologies (Canada)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Macopharma (France)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. HemaCare (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. AllCells (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. StemExpress (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. PPA Research Group (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Leukapheresis Sale, by Type, Application, End User and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Leukapheresis (Value)
      • 7.2.1. Global Leukapheresis by: Type (Value)
        • 7.2.1.1. Leukapheresis Disposables
        • 7.2.1.2. Leukapheresis Devices (Apheresis Devices, Leukapheresis Columns & Cell Separators and Other)
      • 7.2.2. Global Leukapheresis by: Application (Value)
        • 7.2.2.1. Research Institute
        • 7.2.2.2. Therapeutic Applications
      • 7.2.3. Global Leukapheresis by: End User (Value)
        • 7.2.3.1. Academic and Research Institutes
        • 7.2.3.2. Blood Component Providers and Blood Centers
        • 7.2.3.3. Pharmaceutical and Biotechnology Companies
        • 7.2.3.4. Hospitals and Transfusion Centers
      • 7.2.4. Global Leukapheresis Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Leukapheresis: by Type(USD Million)
  • Table 2. Leukapheresis Leukapheresis Disposables , by Region USD Million (2018-2023)
  • Table 3. Leukapheresis Leukapheresis Devices (Apheresis Devices, Leukapheresis Columns & Cell Separators and Other) , by Region USD Million (2018-2023)
  • Table 4. Leukapheresis: by Application(USD Million)
  • Table 5. Leukapheresis Research Institute , by Region USD Million (2018-2023)
  • Table 6. Leukapheresis Therapeutic Applications , by Region USD Million (2018-2023)
  • Table 7. Leukapheresis: by End User(USD Million)
  • Table 8. Leukapheresis Academic and Research Institutes , by Region USD Million (2018-2023)
  • Table 9. Leukapheresis Blood Component Providers and Blood Centers , by Region USD Million (2018-2023)
  • Table 10. Leukapheresis Pharmaceutical and Biotechnology Companies , by Region USD Million (2018-2023)
  • Table 11. Leukapheresis Hospitals and Transfusion Centers , by Region USD Million (2018-2023)
  • Table 12. South America Leukapheresis, by Country USD Million (2018-2023)
  • Table 13. South America Leukapheresis, by Type USD Million (2018-2023)
  • Table 14. South America Leukapheresis, by Application USD Million (2018-2023)
  • Table 15. South America Leukapheresis, by End User USD Million (2018-2023)
  • Table 16. Brazil Leukapheresis, by Type USD Million (2018-2023)
  • Table 17. Brazil Leukapheresis, by Application USD Million (2018-2023)
  • Table 18. Brazil Leukapheresis, by End User USD Million (2018-2023)
  • Table 19. Argentina Leukapheresis, by Type USD Million (2018-2023)
  • Table 20. Argentina Leukapheresis, by Application USD Million (2018-2023)
  • Table 21. Argentina Leukapheresis, by End User USD Million (2018-2023)
  • Table 22. Rest of South America Leukapheresis, by Type USD Million (2018-2023)
  • Table 23. Rest of South America Leukapheresis, by Application USD Million (2018-2023)
  • Table 24. Rest of South America Leukapheresis, by End User USD Million (2018-2023)
  • Table 25. Asia Pacific Leukapheresis, by Country USD Million (2018-2023)
  • Table 26. Asia Pacific Leukapheresis, by Type USD Million (2018-2023)
  • Table 27. Asia Pacific Leukapheresis, by Application USD Million (2018-2023)
  • Table 28. Asia Pacific Leukapheresis, by End User USD Million (2018-2023)
  • Table 29. China Leukapheresis, by Type USD Million (2018-2023)
  • Table 30. China Leukapheresis, by Application USD Million (2018-2023)
  • Table 31. China Leukapheresis, by End User USD Million (2018-2023)
  • Table 32. Japan Leukapheresis, by Type USD Million (2018-2023)
  • Table 33. Japan Leukapheresis, by Application USD Million (2018-2023)
  • Table 34. Japan Leukapheresis, by End User USD Million (2018-2023)
  • Table 35. India Leukapheresis, by Type USD Million (2018-2023)
  • Table 36. India Leukapheresis, by Application USD Million (2018-2023)
  • Table 37. India Leukapheresis, by End User USD Million (2018-2023)
  • Table 38. South Korea Leukapheresis, by Type USD Million (2018-2023)
  • Table 39. South Korea Leukapheresis, by Application USD Million (2018-2023)
  • Table 40. South Korea Leukapheresis, by End User USD Million (2018-2023)
  • Table 41. Taiwan Leukapheresis, by Type USD Million (2018-2023)
  • Table 42. Taiwan Leukapheresis, by Application USD Million (2018-2023)
  • Table 43. Taiwan Leukapheresis, by End User USD Million (2018-2023)
  • Table 44. Australia Leukapheresis, by Type USD Million (2018-2023)
  • Table 45. Australia Leukapheresis, by Application USD Million (2018-2023)
  • Table 46. Australia Leukapheresis, by End User USD Million (2018-2023)
  • Table 47. Rest of Asia-Pacific Leukapheresis, by Type USD Million (2018-2023)
  • Table 48. Rest of Asia-Pacific Leukapheresis, by Application USD Million (2018-2023)
  • Table 49. Rest of Asia-Pacific Leukapheresis, by End User USD Million (2018-2023)
  • Table 50. Europe Leukapheresis, by Country USD Million (2018-2023)
  • Table 51. Europe Leukapheresis, by Type USD Million (2018-2023)
  • Table 52. Europe Leukapheresis, by Application USD Million (2018-2023)
  • Table 53. Europe Leukapheresis, by End User USD Million (2018-2023)
  • Table 54. Germany Leukapheresis, by Type USD Million (2018-2023)
  • Table 55. Germany Leukapheresis, by Application USD Million (2018-2023)
  • Table 56. Germany Leukapheresis, by End User USD Million (2018-2023)
  • Table 57. France Leukapheresis, by Type USD Million (2018-2023)
  • Table 58. France Leukapheresis, by Application USD Million (2018-2023)
  • Table 59. France Leukapheresis, by End User USD Million (2018-2023)
  • Table 60. Italy Leukapheresis, by Type USD Million (2018-2023)
  • Table 61. Italy Leukapheresis, by Application USD Million (2018-2023)
  • Table 62. Italy Leukapheresis, by End User USD Million (2018-2023)
  • Table 63. United Kingdom Leukapheresis, by Type USD Million (2018-2023)
  • Table 64. United Kingdom Leukapheresis, by Application USD Million (2018-2023)
  • Table 65. United Kingdom Leukapheresis, by End User USD Million (2018-2023)
  • Table 66. Netherlands Leukapheresis, by Type USD Million (2018-2023)
  • Table 67. Netherlands Leukapheresis, by Application USD Million (2018-2023)
  • Table 68. Netherlands Leukapheresis, by End User USD Million (2018-2023)
  • Table 69. Rest of Europe Leukapheresis, by Type USD Million (2018-2023)
  • Table 70. Rest of Europe Leukapheresis, by Application USD Million (2018-2023)
  • Table 71. Rest of Europe Leukapheresis, by End User USD Million (2018-2023)
  • Table 72. MEA Leukapheresis, by Country USD Million (2018-2023)
  • Table 73. MEA Leukapheresis, by Type USD Million (2018-2023)
  • Table 74. MEA Leukapheresis, by Application USD Million (2018-2023)
  • Table 75. MEA Leukapheresis, by End User USD Million (2018-2023)
  • Table 76. Middle East Leukapheresis, by Type USD Million (2018-2023)
  • Table 77. Middle East Leukapheresis, by Application USD Million (2018-2023)
  • Table 78. Middle East Leukapheresis, by End User USD Million (2018-2023)
  • Table 79. Africa Leukapheresis, by Type USD Million (2018-2023)
  • Table 80. Africa Leukapheresis, by Application USD Million (2018-2023)
  • Table 81. Africa Leukapheresis, by End User USD Million (2018-2023)
  • Table 82. North America Leukapheresis, by Country USD Million (2018-2023)
  • Table 83. North America Leukapheresis, by Type USD Million (2018-2023)
  • Table 84. North America Leukapheresis, by Application USD Million (2018-2023)
  • Table 85. North America Leukapheresis, by End User USD Million (2018-2023)
  • Table 86. United States Leukapheresis, by Type USD Million (2018-2023)
  • Table 87. United States Leukapheresis, by Application USD Million (2018-2023)
  • Table 88. United States Leukapheresis, by End User USD Million (2018-2023)
  • Table 89. Canada Leukapheresis, by Type USD Million (2018-2023)
  • Table 90. Canada Leukapheresis, by Application USD Million (2018-2023)
  • Table 91. Canada Leukapheresis, by End User USD Million (2018-2023)
  • Table 92. Mexico Leukapheresis, by Type USD Million (2018-2023)
  • Table 93. Mexico Leukapheresis, by Application USD Million (2018-2023)
  • Table 94. Mexico Leukapheresis, by End User USD Million (2018-2023)
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Leukapheresis: by Type(USD Million)
  • Table 106. Leukapheresis Leukapheresis Disposables , by Region USD Million (2025-2030)
  • Table 107. Leukapheresis Leukapheresis Devices (Apheresis Devices, Leukapheresis Columns & Cell Separators and Other) , by Region USD Million (2025-2030)
  • Table 108. Leukapheresis: by Application(USD Million)
  • Table 109. Leukapheresis Research Institute , by Region USD Million (2025-2030)
  • Table 110. Leukapheresis Therapeutic Applications , by Region USD Million (2025-2030)
  • Table 111. Leukapheresis: by End User(USD Million)
  • Table 112. Leukapheresis Academic and Research Institutes , by Region USD Million (2025-2030)
  • Table 113. Leukapheresis Blood Component Providers and Blood Centers , by Region USD Million (2025-2030)
  • Table 114. Leukapheresis Pharmaceutical and Biotechnology Companies , by Region USD Million (2025-2030)
  • Table 115. Leukapheresis Hospitals and Transfusion Centers , by Region USD Million (2025-2030)
  • Table 116. South America Leukapheresis, by Country USD Million (2025-2030)
  • Table 117. South America Leukapheresis, by Type USD Million (2025-2030)
  • Table 118. South America Leukapheresis, by Application USD Million (2025-2030)
  • Table 119. South America Leukapheresis, by End User USD Million (2025-2030)
  • Table 120. Brazil Leukapheresis, by Type USD Million (2025-2030)
  • Table 121. Brazil Leukapheresis, by Application USD Million (2025-2030)
  • Table 122. Brazil Leukapheresis, by End User USD Million (2025-2030)
  • Table 123. Argentina Leukapheresis, by Type USD Million (2025-2030)
  • Table 124. Argentina Leukapheresis, by Application USD Million (2025-2030)
  • Table 125. Argentina Leukapheresis, by End User USD Million (2025-2030)
  • Table 126. Rest of South America Leukapheresis, by Type USD Million (2025-2030)
  • Table 127. Rest of South America Leukapheresis, by Application USD Million (2025-2030)
  • Table 128. Rest of South America Leukapheresis, by End User USD Million (2025-2030)
  • Table 129. Asia Pacific Leukapheresis, by Country USD Million (2025-2030)
  • Table 130. Asia Pacific Leukapheresis, by Type USD Million (2025-2030)
  • Table 131. Asia Pacific Leukapheresis, by Application USD Million (2025-2030)
  • Table 132. Asia Pacific Leukapheresis, by End User USD Million (2025-2030)
  • Table 133. China Leukapheresis, by Type USD Million (2025-2030)
  • Table 134. China Leukapheresis, by Application USD Million (2025-2030)
  • Table 135. China Leukapheresis, by End User USD Million (2025-2030)
  • Table 136. Japan Leukapheresis, by Type USD Million (2025-2030)
  • Table 137. Japan Leukapheresis, by Application USD Million (2025-2030)
  • Table 138. Japan Leukapheresis, by End User USD Million (2025-2030)
  • Table 139. India Leukapheresis, by Type USD Million (2025-2030)
  • Table 140. India Leukapheresis, by Application USD Million (2025-2030)
  • Table 141. India Leukapheresis, by End User USD Million (2025-2030)
  • Table 142. South Korea Leukapheresis, by Type USD Million (2025-2030)
  • Table 143. South Korea Leukapheresis, by Application USD Million (2025-2030)
  • Table 144. South Korea Leukapheresis, by End User USD Million (2025-2030)
  • Table 145. Taiwan Leukapheresis, by Type USD Million (2025-2030)
  • Table 146. Taiwan Leukapheresis, by Application USD Million (2025-2030)
  • Table 147. Taiwan Leukapheresis, by End User USD Million (2025-2030)
  • Table 148. Australia Leukapheresis, by Type USD Million (2025-2030)
  • Table 149. Australia Leukapheresis, by Application USD Million (2025-2030)
  • Table 150. Australia Leukapheresis, by End User USD Million (2025-2030)
  • Table 151. Rest of Asia-Pacific Leukapheresis, by Type USD Million (2025-2030)
  • Table 152. Rest of Asia-Pacific Leukapheresis, by Application USD Million (2025-2030)
  • Table 153. Rest of Asia-Pacific Leukapheresis, by End User USD Million (2025-2030)
  • Table 154. Europe Leukapheresis, by Country USD Million (2025-2030)
  • Table 155. Europe Leukapheresis, by Type USD Million (2025-2030)
  • Table 156. Europe Leukapheresis, by Application USD Million (2025-2030)
  • Table 157. Europe Leukapheresis, by End User USD Million (2025-2030)
  • Table 158. Germany Leukapheresis, by Type USD Million (2025-2030)
  • Table 159. Germany Leukapheresis, by Application USD Million (2025-2030)
  • Table 160. Germany Leukapheresis, by End User USD Million (2025-2030)
  • Table 161. France Leukapheresis, by Type USD Million (2025-2030)
  • Table 162. France Leukapheresis, by Application USD Million (2025-2030)
  • Table 163. France Leukapheresis, by End User USD Million (2025-2030)
  • Table 164. Italy Leukapheresis, by Type USD Million (2025-2030)
  • Table 165. Italy Leukapheresis, by Application USD Million (2025-2030)
  • Table 166. Italy Leukapheresis, by End User USD Million (2025-2030)
  • Table 167. United Kingdom Leukapheresis, by Type USD Million (2025-2030)
  • Table 168. United Kingdom Leukapheresis, by Application USD Million (2025-2030)
  • Table 169. United Kingdom Leukapheresis, by End User USD Million (2025-2030)
  • Table 170. Netherlands Leukapheresis, by Type USD Million (2025-2030)
  • Table 171. Netherlands Leukapheresis, by Application USD Million (2025-2030)
  • Table 172. Netherlands Leukapheresis, by End User USD Million (2025-2030)
  • Table 173. Rest of Europe Leukapheresis, by Type USD Million (2025-2030)
  • Table 174. Rest of Europe Leukapheresis, by Application USD Million (2025-2030)
  • Table 175. Rest of Europe Leukapheresis, by End User USD Million (2025-2030)
  • Table 176. MEA Leukapheresis, by Country USD Million (2025-2030)
  • Table 177. MEA Leukapheresis, by Type USD Million (2025-2030)
  • Table 178. MEA Leukapheresis, by Application USD Million (2025-2030)
  • Table 179. MEA Leukapheresis, by End User USD Million (2025-2030)
  • Table 180. Middle East Leukapheresis, by Type USD Million (2025-2030)
  • Table 181. Middle East Leukapheresis, by Application USD Million (2025-2030)
  • Table 182. Middle East Leukapheresis, by End User USD Million (2025-2030)
  • Table 183. Africa Leukapheresis, by Type USD Million (2025-2030)
  • Table 184. Africa Leukapheresis, by Application USD Million (2025-2030)
  • Table 185. Africa Leukapheresis, by End User USD Million (2025-2030)
  • Table 186. North America Leukapheresis, by Country USD Million (2025-2030)
  • Table 187. North America Leukapheresis, by Type USD Million (2025-2030)
  • Table 188. North America Leukapheresis, by Application USD Million (2025-2030)
  • Table 189. North America Leukapheresis, by End User USD Million (2025-2030)
  • Table 190. United States Leukapheresis, by Type USD Million (2025-2030)
  • Table 191. United States Leukapheresis, by Application USD Million (2025-2030)
  • Table 192. United States Leukapheresis, by End User USD Million (2025-2030)
  • Table 193. Canada Leukapheresis, by Type USD Million (2025-2030)
  • Table 194. Canada Leukapheresis, by Application USD Million (2025-2030)
  • Table 195. Canada Leukapheresis, by End User USD Million (2025-2030)
  • Table 196. Mexico Leukapheresis, by Type USD Million (2025-2030)
  • Table 197. Mexico Leukapheresis, by Application USD Million (2025-2030)
  • Table 198. Mexico Leukapheresis, by End User USD Million (2025-2030)
  • Table 199. Research Programs/Design for This Report
  • Table 200. Key Data Information from Secondary Sources
  • Table 201. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Leukapheresis: by Type USD Million (2018-2023)
  • Figure 5. Global Leukapheresis: by Application USD Million (2018-2023)
  • Figure 6. Global Leukapheresis: by End User USD Million (2018-2023)
  • Figure 7. South America Leukapheresis Share (%), by Country
  • Figure 8. Asia Pacific Leukapheresis Share (%), by Country
  • Figure 9. Europe Leukapheresis Share (%), by Country
  • Figure 10. MEA Leukapheresis Share (%), by Country
  • Figure 11. North America Leukapheresis Share (%), by Country
  • Figure 12. Global Leukapheresis share by Players 2023 (%)
  • Figure 13. Global Leukapheresis share by Players (Top 3) 2023(%)
  • Figure 14. Global Leukapheresis share by Players (Top 5) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Asahi Kasei Medical (Japan) Revenue, Net Income and Gross profit
  • Figure 17. Asahi Kasei Medical (Japan) Revenue: by Geography 2023
  • Figure 18. Fresenius (Germany) Revenue, Net Income and Gross profit
  • Figure 19. Fresenius (Germany) Revenue: by Geography 2023
  • Figure 20. Haemonetics (United States) Revenue, Net Income and Gross profit
  • Figure 21. Haemonetics (United States) Revenue: by Geography 2023
  • Figure 22. Terumo BCT (United States) Revenue, Net Income and Gross profit
  • Figure 23. Terumo BCT (United States) Revenue: by Geography 2023
  • Figure 24. STEMCELL Technologies (Canada) Revenue, Net Income and Gross profit
  • Figure 25. STEMCELL Technologies (Canada) Revenue: by Geography 2023
  • Figure 26. Macopharma (France) Revenue, Net Income and Gross profit
  • Figure 27. Macopharma (France) Revenue: by Geography 2023
  • Figure 28. HemaCare (United States) Revenue, Net Income and Gross profit
  • Figure 29. HemaCare (United States) Revenue: by Geography 2023
  • Figure 30. AllCells (United States) Revenue, Net Income and Gross profit
  • Figure 31. AllCells (United States) Revenue: by Geography 2023
  • Figure 32. StemExpress (United States) Revenue, Net Income and Gross profit
  • Figure 33. StemExpress (United States) Revenue: by Geography 2023
  • Figure 34. PPA Research Group (United States) Revenue, Net Income and Gross profit
  • Figure 35. PPA Research Group (United States) Revenue: by Geography 2023
  • Figure 36. Global Leukapheresis: by Type USD Million (2025-2030)
  • Figure 37. Global Leukapheresis: by Application USD Million (2025-2030)
  • Figure 38. Global Leukapheresis: by End User USD Million (2025-2030)
  • Figure 39. South America Leukapheresis Share (%), by Country
  • Figure 40. Asia Pacific Leukapheresis Share (%), by Country
  • Figure 41. Europe Leukapheresis Share (%), by Country
  • Figure 42. MEA Leukapheresis Share (%), by Country
  • Figure 43. North America Leukapheresis Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Asahi Kasei Medical (Japan)
  • Fresenius (Germany)
  • Haemonetics (United States)
  • Terumo BCT (United States)
  • STEMCELL Technologies (Canada)
  • Macopharma (France)
  • HemaCare (United States)
  • AllCells (United States)
  • StemExpress (United States)
  • PPA Research Group (United States)
Additional players considered in the study are as follows:
Key Biologics (United States) , Caltag Medsystem (United Kingdom) , ZenBio (United States) , Precision for Medicine (United States) , BioIVT (United States)
Select User Access Type

Key Highlights of Report


Apr 2024 233 Pages 61 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Leukapheresis Quantitative research analysis
Global Leukapheresis Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Asahi Kasei Medical (Japan), Fresenius (Germany), Haemonetics (United States), Terumo BCT (United States), STEMCELL Technologies (Canada), Macopharma (France), HemaCare (United States), AllCells (United States), StemExpress (United States) and PPA Research Group (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"The Growth in Demand for Leukopaks in Clinical Research" is seen as one of major influencing trends for Leukapheresis Market during projected period 2023-2030.
The Leukapheresis market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.
Analysts at AMA estimates Leukapheresis Market to reach USD448.1 Million by 2030.

Know More About Global Leukapheresis Report?

Have a Query? Click Here

Other Related Reports

Liver Function Tests Comprehensive Study by Type (Alanine Aminotransferase Test, Aspartate Aminotransferase Test, Alkaline Phosphatase Test, Gamma GT Test, Total Bilirubin, Albumin, Others), Applicat...
$ 3650
Male Infertility Treatment Comprehensive Study by Type (DNA Fragmentation Technique, Oxidative Stress Analysis, Microscopic Examination, Sperm Agglutination, Computer Assisted Semen Analysis, Sperm P...
$ 3800
Jet Lag Treatment Comprehensive Study by Type (Light therapy, Medications), Application (Hospital Pharmacies, Retail Pharmacies, Online Sales, Drug Stores), Drug (Prescription drugs, Melatonin, Her...
$ 3650
Medical Device Cleaning Comprehensive Study by Type (Automatic Cleaning, Manual Cleaning), Application (Hospital, Clinics, Others), Product Type (Enzymatic Detergents, Non-enzymatic Detergents, Alkal...
$ 3650
Animal Model Services Comprehensive Study by Type (Mice, Rats, Fish, Birds, Cattles, Others), Application (Infectious Disease, Immunological Diseases, Cancer, Cardiovascular Diseases, Diabetes, Genet...
$ 3750
Gastrointestinal Cancer Treatment Comprehensive Study by Drug Type (Doxorubicin Hydrochloride, Sunitinib, Docetaxel, Mitomycin, Fluorouracil, Imatinib, Trastuzumab), Therapy (Immunotherapy, Chemother...
$ 3750